GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/IBD/Whole Food Diet Induces Remission in Pediatric and Young Adult Crohn’s Disease

Whole Food Diet Induces Remission in Pediatric and Young Adult Crohn’s Disease

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated January 1, 2025

Quick Answer

Yes, a whole food diet, specifically the Tasty&Healthy (T&H) diet, has been shown to induce remission in pediatric and young adult patients with mild to moderate Crohn’s disease. Here's a detailed explanation based on the TASTI-MM trial: ### Background and Unmet Need: Exclusive enteral nutrition (EEN) is an established treatment for inducing remission in Crohn's disease, but its use is often limited by poor tolerability, especially in children and young...


Yes, a whole food diet, specifically the Tasty&Healthy (T&H) diet, has been shown to induce remission in pediatric and young adult patients with mild to moderate Crohn’s disease. Here's a detailed explanation based on the TASTI-MM trial:

### Background and Unmet Need:

Exclusive enteral nutrition (EEN) is an established treatment for inducing remission in Crohn's disease, but its use is often limited by poor tolerability, especially in children and young adults. This creates a need for alternative dietary approaches that are both effective and more tolerable.

### Tasty&Healthy (T&H) Diet Concept:

The T&H diet is a whole food-based dietary intervention that excludes processed foods, gluten, red meat, and dairy while avoiding the need for formula-based nutrition. It is designed to be palatable and easier to adhere to, making it a more practical option for patients.

### Study Design:

The TASTI-MM trial was a multicenter, clinician-blinded, randomized controlled trial that compared the T&H diet with EEN in biologic-naïve patients aged 6–25 years with mild to moderate Crohn’s disease. The trial aimed to evaluate tolerability, clinical remission rates, and other health outcomes over an 8-week induction period.

### Key Findings:

1. **Tolerability and Adherence:**

  • The T&H diet was significantly better tolerated than EEN.
  • A substantially higher proportion of patients completed the 8-week intervention in the T&H group compared to the EEN group.
  • Most discontinuations in the EEN group occurred within the first four weeks, highlighting early intolerance issues.

2. **Clinical Remission Rates:**

  • Both diets achieved similar rates of symptomatic remission at week 8 in intention-to-treat analyses.
  • Among patients who completed the therapy (per-protocol analysis), remission rates were high and comparable between the two dietary approaches.

3. **Biological and Noninvasive Markers:**

  • Markers of inflammation, such as calprotectin, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), improved significantly in both groups.
  • Noninvasive markers of mucosal inflammation, such as the MINI index, showed comparable improvement in both groups.

4. **Microbiome Effects:**

  • The T&H diet promoted gut microbiome stability over time, whereas microbial diversity declined in the EEN group.
  • T&H increased microbial richness and diversity, which are associated with better gut health.
  • Proinflammatory bacterial species decreased, and beneficial species linked to intestinal health and mucosal healing were enriched in the T&H group.

5. **Dietary Pattern and Nutritional Benefits:**

  • The T&H diet increased fiber and potassium intake, reflecting a shift toward minimally processed, plant-based foods.
  • This dietary pattern aligns with general recommendations for promoting gut health and reducing inflammation.

6. **Quality of Life and Patient Satisfaction:**

  • Quality-of-life scores improved in both groups, with no significant differences between them.
  • Patients reported higher satisfaction with the T&H diet compared to EEN, likely due to its palatability and flexibility.

7. **Safety Profile:**

  • Both dietary interventions were safe, with only mild adverse events reported.

### Clinical Implications:

The T&H diet represents a feasible, effective, and well-tolerated alternative to exclusive enteral nutrition for inducing remission in pediatric and young adult patients with mild to moderate Crohn’s disease. Its benefits include greater adherence, improved patient satisfaction, and positive effects on the gut microbiome, making it a promising option for nutrition therapy in this population.

In summary, the T&H diet offers a whole food-based approach that is not only effective in inducing remission but also addresses the limitations of EEN by improving tolerability and quality of life for patients.

Related Q&A

IBD Across Ethnicities: Gastroenterology | July 2026

Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...

Moving Beyond the "Wait to Fail" Strategy in ASUC: FG | 2026

Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...

FMT in Ulcerative Colitis: JGH | July 2026

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...

Engineering Immune Cell Therapies for IBD: Nat Re Gastroe & Hepato | June 2026

Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...

Real-World IBD Patients Rarely Meet Clinical Trial Criteria: AJG | June 2026

Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...

Mirikizumab in Ulcerative Colitis: JCC | June 2026

Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer